CT2Trachospray: Soft Mist Spray Device for Airway Anaesthesia During Awake Videolaryngoscopy

Sponsor
Radboud University Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05478122
Collaborator
(none)
20
1
1
3.2
6.2

Study Details

Study Description

Brief Summary

Rationale:

Effective and fast topical anaesthesia of the upper airway is of paramount importance in awake (conscious) videolaryngoscopy of the airway in order to avoid patient discomfort. Different methods of anesthetizing the airway have been described. Conventional topical airway anaesthesia is not always effective due to non-optimal flow patterns and generation of ineffective local anaesthetic aerosols. Other methods of anaesthetizing the airway are more invasive. In order to optimize topical anaesthesia of the airway a soft mist spray device (Trachospray) for topical anaesthesia of the airway has been developed, in which optimal airflow patterns are obtained and local anaesthetic aerosols are generated which will reach the target zone for anesthetizing the airway.

Objective: In this study, the Trachospray will be used for awake videolaryngoscopy, to evaluate its use, effectiveness and comfort level for patients and anaesthesiologist.

Study design: Interventional study.

Study population: 20 healthy human volunteers, ASA 1, 18-60 years old.

Intervention: Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device

Main study parameters/endpoints:

Anaesthesia of the airway as evaluated with successful awake videolaryngoscopy with minimal discomfort for the subject.

Nature and extent of the burden and risks associated with participation:

Risk management on the Trachospray device shows that all user risks are mitigated and no residual risks remain for the use of the device. Testing of the device and the application of the device in daily practice has no additional risks than the present technique of performing anaesthesia of the airways.There may be some discomfort during the procedure, mainly airway irritation which may cause coughing or gag reflex.

Condition or Disease Intervention/Treatment Phase
  • Device: Trachospray for awake videolaryngoscopy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Soft Mist Spray Device for Airway Anaesthesia During Awake Videolaryngoscopy
Anticipated Study Start Date :
Jul 25, 2022
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Oct 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Interventional

Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device

Device: Trachospray for awake videolaryngoscopy
Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device

Outcome Measures

Primary Outcome Measures

  1. Complete anaesthesia of the airway as evaluated with successful awake videolaryngoscopy with minimal discomfort for the subject [3 months]

    Discomfort and level of anesthesia will be measured with a numerical rating scale (NRS). 60 / 5.000 Vertaalresultaten So the result will be displayed in whole numbers.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age between 18-60 years

  • Lean body weight >= 50 kg

  • ASA physical status 1

Exclusion Criteria:
  • Inability to cooperate with adequate airway assessment,

  • History of hepatic, renal and coagulation diseases,

  • Respiratory tract pathology

  • Pregnancy

  • Risk of regurgitation or aspiration

  • Allergy to amide type of local anaesthetics

  • No written informed consent by subject

Contacts and Locations

Locations

Site City State Country Postal Code
1 Radboudumc Nijmegen Netherlands

Sponsors and Collaborators

  • Radboud University Medical Center

Investigators

  • Principal Investigator: Geert-Jan van Geffen, Radboud University Medical Center (Radboudumc)
  • Study Director: Hielke Markerink, Radboud University Medical Center (Radboudumc)

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Radboud University Medical Center
ClinicalTrials.gov Identifier:
NCT05478122
Other Study ID Numbers:
  • CT2 Trachospray
First Posted:
Jul 28, 2022
Last Update Posted:
Aug 2, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Aug 2, 2022